OUR SCIENCE

CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition
David Gallo et al. Nature. April 2022

RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Anne Roulston, et al. Molecular Cancer Therapeutics. 2021

CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition
David Gallo et al. April 2020

Identifying functional loss of ATM gene in patients with advanced cancer.
Patrick Glen Pilie et al. ASCO. 2020

Honing in on PARPi response in Prostate Cancer: from HR pathway- to gene-by-gene granularity
Alexandra O, et al. Clinical Cancer Research. May 1 2020 DOI: 10.1158/1078-0432.CCR-20-0707

Pan-cancer analysis of whole genomes.
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Nature. 2020; 578(7793):82–93. doi:10.1038/s41586-020-1969-6

Synthetic lethality as an engine for cancer drug target discovery.

Huang A, Garraway LA, Ashworth A, Weber B. Nat Rev Drug Discov. 2020;19(1):23–38

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.

Wengner AM, Siemeister G, Lücking U, et al. Mol Cancer Ther. 2020;19(1):26–38.

CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions.

Su D, Feng X, Colic M, et al. DNA Repair (Amst). 2020;87:102803.

A CRISPR Way to Identify Cancer Targets.

Hahn WC. N Engl J Med. 2019;380(25):2475–2477.

First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

J S. De Bono et al. Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 3007-3007

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

TA Knijnenburg et al. Cell Rep 23 (1), 239-254.e6. 2018

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. 

Zehir A, Benayed R, Shah RH, et al. Nat Med. 2017;23(6):703–713.

Synthetic lethality in lung cancer and translation to clinical therapies. 

Leung AW, de Silva T, Bally MB, Lockwood WW. Mol Cancer. 2016;15(1):61. Published 2016 Sep 29.

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.

Hart T, Chandrashekhar M, Aregger M, et al. Cell. 2015;163(6):1515–1526.

The concept of synthetic lethality in the context of anticancer therapy. 

Kaelin WG Jr. Nat Rev Cancer. 2005;5(9):689–698.

Global mapping of the yeast genetic interaction network.

Tong AH, Lesage G, Bader GD, et al. Science. 2004;303(5659):808–813.